Anti-Human CD40 Recombinant Antibody (chi220) (CAT#: TAB-188LC)

Figure 1 The results of in vitro assays testing chimeric and humanized antibody.

The binding of chi220 and h220v3 to hCD40-mG2b in an ELISA based assay.

Figure 2 The results of in vitro assays testing chimeric and humanized antibody.

The inhibition of sgp39-mediated costimulation of human B cells with anti-human CD40 mAbs.

Figure 3 The IgM Anti-SRBC antibody response.

FIG. A shows the results from monkeys that received 10, 40 or 100 mg/kg chi220. FIG. B shows the results from monkeys that received 0.1 or 1 mg/kg chi220.

Figure 4 The IgG Anti-SRBC antibody response.

FIG. A shows the results from monkeys that received 10, 40 or 100 mg/kg chi220. FIG. B shows the results from monkeys that received 0.1 or 1 mg/kg chi220.

Figure 5 The anti-OVA antibody response in primates.

FIG. A shows the results of analysis for IgM anti-OVA antibodies. FIG. B shows the results of analysis for IgG anti-OVA antibodies.

Figure 6 The anti-KLH antibody response in primates.

FIG. A shows the results of analysis for IgM anti-KLH antibodies. FIG. B shows the results of analysis for IgG anti-KLH antibodies.

Figure 7 A graph showing peripheral B cell count of rhesus macaques treated with mouse-rhesus chimeric forms of 2C10 engineered to contain either rhesus IgG1 (2C1OR1) or IgG4 (2C10R4) heavy chain constant regions, and chimeric IgGl forms of anti-CD40 3A8 (3A8R1) or anti-CD40 Chi220 (Chi220).

All animals were immunized with 4-hydroxy-3-nitrophenylacetyl-conjugated keyhole limpet hemocyanin (KLH) after the first antibody treatment.

Figure 8 A graph showing results from a competitive blockade assay using human PBMCs incubated with increasing concentrations of 2C10, 3A8, or Chi220 antibodies and stained with an APC- conjugated 2C10 to assess the ability of each antibody to cross-block 2C10.